Efficacy and safety of nintedanib for older adults with idiopathic pulmonary fibrosis or progressive fibrosing interstitial lung disease: A multicenter retrospective study in Japan - PubMed

4 hours ago

Nintedanib shows similar efficacy in slowing annual FVC decline in older (≥75 years) and younger (<75 years) Japanese patients with IPF or PF-ILD.
Adverse event rates were comparable between age groups, though older patients more often required dose reductions or had shorter treatment durations.
Median survival was shorter in older patients (1054 days vs. 1400 days), likely due to reduced physiological reserve rather than treatment efficacy.
The study supports nintedanib use in older adults, indicating manageable safety and maintained effectiveness in real-world clinical practice.

Hasty Briefsbeta